ロード中...
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were dev...
保存先:
| 出版年: | Rheumatology (Oxford) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098113/ https://ncbi.nlm.nih.gov/pubmed/33950228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa893 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|